Trial Profile

A Dose-finding Trial Evaluating the Effect and Safety of Once-weekly Treatment of Somapacitan Compared to Daily Norditropin in Children With Short Stature Born Small for Gestational Age With no Catch-up Growth by 2 Years of Age or Older

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Mar 2024 Planned End Date changed from 12 May 2025 to 23 Dec 2026.
10 Jan 2023 Results assessing the efficacy, safety, and tolerability of 3 once-weekly somapacitan doses compared with daily growth hormone (GH) administration in short children born small for gestational age, published in the European Journal of Endocrinology.
11 Nov 2022 Planned End Date changed from 25 Apr 2025 to 12 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com